Home » Harvard Health Blog » Robert Goldstein, MD, PhD, Author at Harvard Health Blog

Robert Goldstein, MD, PhD

Robert Goldstein, MD, PhD
Contributor

Dr. Robert Goldstein (he/him/his) is an instructor in Medicine at Harvard Medical School and serves as the medical director of the Transgender Health Program at Massachusetts General Hospital. Dr. Goldstein received his undergraduate degree, MD, and PhD at Tufts University before coming to MGH for internship, residency, and chief residency. He completed the combined MGH/BWH infectious disease fellowship in the HIV clinician educator track, and joined the faculty in 2018 as an infectious disease physician and primary care provider in the Transgender Health Program. His clinical practice is focused on caring for the LGBTQ community, those living with HIV, and those at risk for HIV.

Posts by Robert Goldstein, MD, PhD

U=U: Ending stigma and empowering people living with HIV

Rose McKeon Olson, MD

Contributor
Robert Goldstein, MD, PhD

Contributor
Close up of arms of two men painted red and shaped as red ribbon, symbol of solidarity for those living with HIV/AIDS

People living with HIV can suppress the virus by taking medication daily. If the level of virus in a person’s blood is suppressed successfully, research shows that the virus isn’t passed on to others. U=U means “undetectable equals untransmittable.”

Read more »

Sexually transmitted infections are on the rise: Should you worry?

Eric A. Meyerowitz, MD

Contributor
Robert Goldstein, MD, PhD

Contributor
Sexual health written on blackboard with stethoscope placed on top

The number of sexually transmitted infections reported in the US reached an all-time high last year. Having an STI can raise a person’s risk of getting HIV or having infertility or pregnancy complications, but STIs are preventable and treatable. Knowing the facts about STIs and testing is the first step.

Read more »

PrEP prevents HIV — so why aren’t more people taking it?

Robert Goldstein, MD, PhD

Contributor

PrEP (pre-exposure prophylaxis) is a daily medication taken to prevent HIV infection. While multiple studies show PrEP is effective, relatively few of those who might benefit are taking it. Will a 10-year initiative to reduce rates of HIV and a new formulation of PrEP help?

Read more »